Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index

European Journal of Neurology

Volumn 23, Issue 4, 2016, Pages 722-728

  de Bock, L ^a   Fraussen, J ^a   Villar, L M ^b   Alvarez Cermeno J C ^b   Van Wijmeersch, B ^a,c   van Pesch, V ^d   Stinissen, P ^a   Somers, V ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Multiple Sclerosis and Rehab Center   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Autoantibodies; Biomarker; Multiple sclerosis; SPAG16

Indexed keywords

BIOLOGICAL MARKER; GLATIRAMER; INTERFERON; NATALIZUMAB; SPERM ANTIBODY; SPERM ASSOCIATED ANTIGEN 16 ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; MICROTUBULE ASSOCIATED PROTEIN; SPAG16 PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; BLOOD; DISEASE COURSE; IMMUNOLOGY; MIDDLE AGED;

ADULT; AUTOANTIBODIES; BIOMARKERS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84952673782     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12925     Document Type: Article

References (25)

1. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-218.
2. Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev 2014; 13: 518-524.
3. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647-656.
4. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-2712.
5. Hawa M, Beyan H, Leslie RD. Principles of autoantibodies as disease-specific markers. Autoimmunity 2004; 37: 253-256.
6. Somers V, Govarts C, Somers K, Hupperts R, Medaer R, Stinissen P. Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates. J Immunol 2008; 180: 3957-3963.
7. Pennarun G, Bridoux AM, Escudier E, et al. Isolation and expression of the human hPF20 gene orthologous to Chlamydomonas PF20: evaluation as a candidate for axonemal defects of respiratory cilia and sperm flagella. Am J Respir Cell Mol Biol 2002; 26: 362-370.
8. Knevel R, Klein K, Somers K, et al. Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Ann Rheum Dis 2014; 73: 2038-2046.
9. Uhlen M, Bjorling E, Agaton C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005; 4: 1920-1932.
10. de Bock L, Somers K, Fraussen J, et al. Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosis. J Immunol 2014; 193: 2147-2156.
11. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
12. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
14. Fraussen J, Claes N, de Bock L, Somers V. Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 2014; 13: 1126-1137.
15. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012; 367: 115-123.
16. Rouwette M, Noben JP, Van Horssen J, et al. Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis. J Neurochem 2013; 126: 483-492.
17. Quintana FJ, Farez MF, Viglietta V, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 2008; 105: 18889-18894.
18. Trentini A, Comabella M, Tintore M, et al. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol 2014; 261: 2338-2343.
19. Cepok S, Jacobsen M, Schock S, et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001; 124: 2169-2176.
20. Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003; 53: 222-226.
21. Villar LM, Casanova B, Ouamara N, et al. Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol 2014; 76: 231-240.
22. Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44: 980-983.
23. Miljkovic D, Timotijevic G, Mostarica Stojkovic M. Astrocytes in the tempest of multiple sclerosis. FEBS Lett 2011; 585: 3781-3788.
24. Claycomb KI, Johnson KM, Winokur PN, Sacino AV, Crocker SJ. Astrocyte regulation of CNS inflammation and remyelination. Brain Sci 2013; 3: 1109-1127.
25. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.